logo
Share SHARE
FONT-SIZE Plus   Neg

Pfizer's Phase 3 Study Of Torisel In Combination With Bevacizumab Fails

Pfizer Inc (PFE) Friday announced that its Phase 3 INTORACT trial , evaluating the combination of bevacizumab plus TORISEL compared with bevacizumab plus interferon-alfa-2a, or IFN-a-2a, did not meet its primary endpoint of superiority in extending progression free survival , or PFS, in the study population.

The company stated that the Phase 3 trial was carried out in the first-line treatment of patients with advanced renal cell carcinoma, or RCC, across risk groups.

The company further stated that the combination of bevacizumab and IFN-a-2a is approved as first-line treatment for advanced RCC and clinical supplies of both of these drugs in this trial were provided through an agreement with Roche.

"This trial advances our knowledge about the role and limitations of combining targeted therapies in the treatment of advanced RCC," said Dr. Mace Rothenberg, senior vice president of clinical development and medical affairs for Pfizer's Oncology Business Unit. "Additional analyses will be performed to help us understand this result. The study outcome, involving combination therapy, does not change the safety and efficacy relationship of single-agent TORISEL for advanced RCC patients with a poor prognostic risk profile."

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Shares of Telefonaktiebolaget LM Ericsson gained around 4 percent in the morning trading in Stockholm after Swedish telecom equipment maker announced Monday the departure of Hans Vestberg as its President and CEO as well as a Board member, with immediate effect. The move follows a sharp decline in its second quarter profit that triggered significant cost cut initiatives. Dutch consumer electronics giant Philips Electronics NV reported Monday significantly higher profit in its second quarter, mainly with Funai arbitration award, despite weak sales. Comparable sales growth was 3 percent with improved HealthTech portfolio, despite weakness in Lighting. The company also maintained its outlook for fiscal 2016. Jeff Bezos, the CEO of Amazon, has overtaken Berkshire Hathaway's founder Warren Buffet to become the third-richest person in the world, according to the Bloomberg Billionaires Index. Bezos is now behind clothing retailer Zara's founder Amancio Ortega, who is now second, and Bill Gates, co-founder...
comments powered by Disqus
Follow RTT